Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy-Reference-Cited by-同舟云学术

Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy

Published:2002-03 Issue:3 Volume:46 Page:896-899
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

van Praag Rieneke M. E.¹,van Weert Elisabeth C. M.¹,van Heeswijk Rolf P. G¹,Zhou Xiao-Jian²,Sommadossi Jean-Pierre²,Jurriaans Suzanne³,Lange Joep M. A.¹³,Hoetelmans Richard M. W.⁴,Prins Jan M.¹

Affiliation:

1. National Aids Therapy Evaluation Center (NATEC), Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS

2. Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama

3. Department of Human Retrovirology, Academic Medical Center, University of Amsterdam

4. Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands

Abstract

ABSTRACT For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy. While studies suggest that saquinavir concentrations decrease over time, we show that concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid are stable during 2 years of therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.3.896-899.2002

Reference20 articles.

1. Antonelli, G., O. Turriziani, A. Verri, P. Narciso, F. Ferri, G. D'Offizi, and F. Dianzani. 1996. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res. Hum. Retrovir.12:223-228.

2. Back, D. J., S. H. Khoo, S. E. Gibbons, and C. Merry. 2001. The role of therapeutic drug monitoring in treatment of HIV infection. Br. J. Clin. Pharmacol.51:301-308.

3. Gibaldi M. 1991. Biopharmaceutics and clinical pharmacokinetics 4th ed. p. 14-23. Lea & Febiger Philadelphia Pa.

4. Gisolf, E. H., R.P.G. van Heeswijk, R. M. W. Hoetelmans, and S. A. Danner. 2000. Decreased exposure to saquinavir in HIV-1-infected patients after long term antiretroviral therapy including ritonavir and saquinavir. AIDS14:801-806.

5. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, A. Meibohm, J. H. Condra, F. T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E. A. Emini, J. A. Chodakewitz, R. Isaacs, and D. D. Richman. 2000. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med.133:35-39.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zidovudine protects hyperosmolarity-stressed human corneal epithelial cells via antioxidant pathway;Biochemical and Biophysical Research Communications;2018-05

2. CNS penetration of ART in HIV-infected children;Journal of Antimicrobial Chemotherapy;2017-11-08

3. Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain;Retrovirology;2017-10-16

4. Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1;Cell Cycle;2017-04-20

5. The dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C);Oncotarget;2017-03-23